Ozempic face
What the FDA labels record as adverse events, each one tied back to the evidence it came from.
Definition
The popular name for facial volume loss during rapid weight loss on a GLP-1. A 2025 Otolaryngology imaging cohort (PMID 40407186) put it at a median 9% midfacial volume loss, around 7% per 10 kg lost. It is fat leaving the face, not a drug toxicity — slower titration and a slower loss curve reduce it.
Ozempic face: facial volume loss evidence →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under Side effects
Where the evidence lives
- Ozempic face: facial volume loss evidence
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers